Treatment of short bowel syndrome patients with colon-in-continuity

Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

We claim: 
     
         1 . A method of treating a patient having short bowel syndrome with vascular ischemia, who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering h(Gly2)GLP-2 to said patient using a dosing regimen effective to reduce or eliminate said weekly amount of parenteral nutrition received by said patient. 
     
     
         2 . A method as defined in  claim 1 , wherein the h(Gly2)GLP-2 is administered at a daily dose of from 5 to 500 μg/kg. 
     
     
         3 . A method as defined in  claim 2 , wherein the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg. 
     
     
         4 . A method as defined in  claim 1 , wherein the h(Gly2)GLP-2 is administered by subcutaneous injection. 
     
     
         5 . A method as defined in  claim 4 , wherein the subcutaneous injection is into the abdomen, thigh, or arm. 
     
     
         6 . A method as defined in  claim 1 , wherein the patient is an adult. 
     
     
         7 . A method of treating a patient having short bowel syndrome with vascular ischemia, who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering h(Gly2)GLP-2 to said patient using a dosing regimen effective to increase wet weight absorption compared to a baseline wet weight absorption by said patient. 
     
     
         8 . A method as defined in  claim 7 , wherein the h(Gly2)GLP-2 is administered at a daily dose of from 5 to 500 μg/kg. 
     
     
         9 . A method as defined in  claim 8 , wherein the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg. 
     
     
         10 . A method as defined in  claim 7 , wherein the h(Gly2)GLP-2 is administered by subcutaneous injection. 
     
     
         11 . A method as defined in  claim 10 , wherein the subcutaneous injection is into the abdomen, thigh, or arm. 
     
     
         12 . A method as defined in  claim 7 , wherein the patient is an adult. 
     
     
         13 . A method as defined in  claim 1 , wherein said regimen comprises administration of said h(Gly2)GLP-2 over a period of at least 21 days. 
     
     
         14 . A method as defined in  claim 7 , wherein said regimen comprises administration of said h(Gly2)GLP-2 over a period of at least 21 days. 
     
     
         15 . A method as defined in  claim 1 , wherein the parenteral nutrition is reduced by volume or frequency of administration. 
     
     
         16 . A method as defined in  claim 1 , wherein said patient is an adult and the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection. 
     
     
         17 . A method as defined in  claim 7 , wherein said patient is an adult and the h(Gly2)GLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.